MTOR and breast carcinoma: Although the mammalian target of rapamycin (mTOR) inhibitor everolimus and the cyclin‐dependent kinase 4/6 inhibitor palbociclib have been used to prevent endocrine resistance in breast cancer [2], these drugs also have some side effects.